Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome

NCT02269592 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02269592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome
Lead sponsor
Dana-Farber Cancer Institute
Phase
Observational
Overall status
Recruiting
Start date
August 31, 2014
Completion date
September 30, 2030
Enrollment
10,000 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancy, low-grade, hematological malignancies, igg monoclonal gammopathy of uncertain significance, monoclonal gammopathy of undetermined significance (mgus), myelodysplastic syndrome with low-grade lesions, myelodysplastic syndromes, smoldering multiple myeloma, waldenstrom macroglobulinemia